Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Roche: The End Of An Era

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche offers to buy out Genentech’s minority stakeholders for $89 per share, or $43.7 billion, to create the seventh largest U.S. pharma company.

You may also be interested in...



Roche Wins Genentech, But Will Biotech Employees Remain?

After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake

Roche Wins Genentech, But Will Biotech Employees Remain?

After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake

Roche Wins Genentech, But Will Biotech Employees Remain?

With a sweetened bid, the Swiss pharma gains the blessing of Genentech’s special committee, but whether the innovator’s valuable staffers sanction the union is an open question.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel